Grand challenge commentary: Synthetic immunology to engineer human immunity.

Rationally designing new strategies to control the human immune response stands as a key challenge for the scientific community. Chemical biologists have the opportunity to address specific issues in this area that have important implications for both basic science and clinical medicine.

[1]  S. Danishefsky,et al.  Synthetic carbohydrate-based anticancer vaccines: the Memorial Sloan-Kettering experience , 2009, Expert review of vaccines.

[2]  P. Kantoff,et al.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer. , 2010, The New England journal of medicine.

[3]  E. Schmitt,et al.  A synthetic vaccine consisting of a tumor-associated sialyl-T(N)-MUC1 tandem-repeat glycopeptide and tetanus toxoid: induction of a strong and highly selective immune response. , 2009, Angewandte Chemie.

[4]  M. Busslinger,et al.  Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors , 2007, Nature.

[5]  W. L. Jorgensen,et al.  A remote arene-binding site on prostate specific membrane antigen revealed by antibody-recruiting small molecules. , 2010, Journal of the American Chemical Society.

[6]  J. Brown,et al.  Optimized clostridium-directed enzyme prodrug therapy improves the antitumor activity of the novel DNA cross-linking agent PR-104. , 2008, Cancer research.

[7]  Y. Shi,et al.  Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells , 2009, Clinical and experimental immunology.

[8]  P. Schultz,et al.  Directed embryonic stem cell differentiation with small molecules. , 2010, Future medicinal chemistry.

[9]  S. Schreiber,et al.  Small molecules efficiently direct endodermal differentiation of mouse and human embryonic stem cells. , 2009, Cell stem cell.

[10]  Philip S Low,et al.  Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. , 2008, Accounts of chemical research.

[11]  A. Górski,et al.  Bacteriophages and cancer , 2010, Archives of Microbiology.

[12]  Jason K. Pontrello,et al.  Activating B cell signaling with defined multivalent ligands. , 2007, ACS chemical biology.

[13]  R. M. Owen,et al.  Selective tumor cell targeting using low-affinity, multivalent interactions. , 2007, ACS chemical biology.

[14]  H. Blau,et al.  Nuclear reprogramming to a pluripotent state by three approaches , 2010, Nature.

[15]  Sheng Ding,et al.  Evolution of induced pluripotent stem cell technology , 2010, Current opinion in hematology.

[16]  B. González,et al.  Instant immunity through chemically programmable vaccination and covalent self-assembly , 2009, Proceedings of the National Academy of Sciences.

[17]  M. Adams,et al.  Design and synthesis of potent Quillaja saponin vaccine adjuvants. , 2010, Journal of the American Chemical Society.

[18]  G. S. Hunt,et al.  Mechanistic studies of the immunochemical termination of self-tolerance with unnatural amino acids , 2009, Proceedings of the National Academy of Sciences.

[19]  T. Kodadek.  Development of antibody surrogates for the treatment of cancers and autoimmune disease. , 2010, Current opinion in chemical biology.